Indication · alzheimer's disease

alzheimer's disease FDA approvals, PDUFA dates and pipeline.

Updated Snapshot 20261116T112050ZBuilt

We track 8 alzheimer's disease drugs. No FDA approvals recorded yet.

Drugs

Upcoming catalysts

DateDrugCompanyEventIndicationStatusSource
May 2028Month disclosedNBI-1117567NBIXPrimary completionAlzheimer's DiseaseScheduledClinicalTrials.gov
May to Aug 2028Quarter disclosedNBI-1117567NBIXTopline readoutAlzheimer's DiseaseScheduledClinicalTrials.gov
Sep to Dec 2028Quarter disclosedkarxt (BMS-986510)BMYTopline readoutAlzheimer's DiseaseScheduledClinicalTrials.gov
Sep to Dec 2028Quarter disclosedkarxt (BMS-986510)BMYTopline readoutAlzheimer's DiseaseScheduledClinicalTrials.gov
Sep to Dec 2028Quarter disclosedGSK4527226GSKTopline readoutAlzheimer's DiseaseScheduledClinicalTrials.gov
Sep to Dec 2028Quarter disclosedVHB937NVSTopline readoutAlzheimer's DiseaseScheduledClinicalTrials.gov
September 2028Month disclosedkarxt (BMS-986510)BMYPrimary completionAlzheimer's DiseaseScheduledClinicalTrials.gov
September 2028Month disclosedkarxt (BMS-986510)BMYPrimary completionAlzheimer's DiseaseScheduledClinicalTrials.gov
September 2028Month disclosedVHB937NVSPrimary completionAlzheimer's DiseaseScheduledClinicalTrials.gov
September 2028Month disclosedGSK4527226GSKPrimary completionAlzheimer's DiseaseScheduledClinicalTrials.gov
Nov 2028 to Feb 2029Quarter disclosedxanomeline/trospium chloride (BMS-986510)BMYTopline readoutAlzheimer's DiseaseScheduledClinicalTrials.gov
November 2028Month disclosedxanomeline/trospium chloride (BMS-986510)BMYPrimary completionAlzheimer's DiseaseScheduledClinicalTrials.gov
April 2029Month disclosedremternetug (LY3372993)LLYPrimary completionAlzheimer's DiseaseScheduledClinicalTrials.gov
Apr to Jul 2029Quarter disclosedremternetug (LY3372993)LLYTopline readoutAlzheimer's DiseaseScheduledClinicalTrials.gov

Past catalysts and decisions

DateDrugCompanyEventIndicationStatusSource
May 14, 2026GSK4527226GSKPrimary completionAlzheimer's DiseaseWithdrawnClinicalTrials.gov
late 2024Half-year disclosedPMN310PMNTrial startAlzheimer's diseaseScheduledSEC 8-K Exhibit 99.1

All indications · Approval rates by indication

Questions

What alzheimer's disease drugs have upcoming PDUFA dates?

None disclosed.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.